{
  "abstract": "Background and Objectives: As adjuvant treatment for human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (eBC) evolves, real-world data should inform olaparib utilization, sequencing, and combination patterns in clinical practice. Methods: Using Komodo US claims data (1 January 2019-31 December 2023), we retrospectively analyzed HER2-negative eBC patients on adjuvant olaparib. Continuous insurance for 12 months pre- and ≥30 days post-index date (first olaparib prescription), with follow-up through disenrollment or study end, was required. Outcomes, including time on therapy (Kaplan-Meier median persistence), adherence (proportion of days covered), dose reduction, and combination patterns, were stratified by claims-derived hormone-receptor-positive (HR+) and triple-negative BC (TNBC) status. Results: Among 176 olaparib-treated patients (median age, 44 years), the median (95% CI) time on therapy was 11.0 (9.2, 12.2) months; 27.3% (n = 48) discontinued before 12 months without re-initiating, 19.9% experienced a dose reduction, and median adherence was 90%. Olaparib was combined with other therapies in 48.3% (n = 85) (29.6% [32/108] of TNBC and 77.9% [53/68] of HR+ patients), most often with immunotherapy in TNBC (81.3%, n = 26) and endocrine therapy in HR+ (88.7%, n = 47). Conclusions: Real-world data suggest favorable persistence and dosing patterns with adjuvant olaparib. Future research should prioritize olaparib combination regimen safety and effectiveness.",
  "abstract_shown": true,
  "affiliations": [
    "Mayo Clinic Hospital, Phoenix, AZ 85054, USA.",
    "AstraZeneca, Gaithersburg, MD 20878, USA.",
    "Merck Sharp & Dohme LLC, A Subsidiary of Merck & Co., Inc., Rahway, NJ 07065, USA.",
    "Cencora, Conshohocken, PA 19428, USA."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 8,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Felipe Batalini",
      "orcid": "0000-0003-3354-308X"
    },
    {
      "affs": [
        1
      ],
      "name": "Qixin Li",
      "orcid": "0009-0007-4522-1594"
    },
    {
      "affs": [
        1
      ],
      "name": "Jennifer F Hayes"
    },
    {
      "affs": [
        2
      ],
      "name": "Kathryn Mishkin"
    },
    {
      "affs": [
        3
      ],
      "name": "Neel Vaidya",
      "orcid": "0000-0002-5697-5881"
    },
    {
      "affs": [
        3
      ],
      "name": "Dana Stafkey"
    },
    {
      "affs": [
        3
      ],
      "name": "Eileen Farrelly"
    },
    {
      "affs": [
        1
      ],
      "name": "Xiaoqing Xu"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/8w6gnf2f65hes.bib",
  "cited_by": 0,
  "doi": "10.3390/curroncol33100589",
  "fulltext_url": "https://europepmc.org/articles/PMC13702983",
  "id": "8w6gnf2f65hes",
  "issns": [
    "1198-0052",
    "1718-7729"
  ],
  "landing_url": "https://europepmc.org/article/MED/42930156",
  "language": "eng",
  "licence": "CC-BY",
  "licence_label": "CC BY",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2730|PARP inhibition in cancer therapy"
    ]
  ],
  "openalex": "W7214894050",
  "pdf_url": "https://europepmc.org/articles/PMC13702983?pdf=render",
  "pmcid": "PMC13702983",
  "pmid": "42930156",
  "published": "2026-09-30",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/8w6gnf2f65hes.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:22:01Z",
      "native_id": "MED:42930156",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42930156"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2730|PARP inhibition in cancer therapy",
      "subfield": "oncology"
    }
  ],
  "title": "Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database.",
  "title_text": "Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:22:01Z",
  "url": "https://research.draconitic.com/paper/8w6gnf2f65hes",
  "venue": "Current oncology (Toronto, Ont.)",
  "versions": []
}